The National Institutes of Health (NIH) invites applications for the Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) under Funding Opportunity Announcement PAR-22-182. This program aims to support behavioral intervention research in areas such as drug abuse treatment, adherence interventions, and substance misuse treatment. The research should focus on testing efficacy, conducting clinical trials, examining mechanisms of behavior change, determining dose-response, optimizing treatment, and sequencing behavioral or integrated pharmacological and behavioral interventions. Specific areas of interest include interventions targeting comorbidities, leveraging technology for sustainability, promoting HIV prevention, and addressing chronic pain.
Applications can address interventions for (1) drug abuse treatment; (2) treatment adherence, including using technology to improve outcomes; (3) prevention of HIV acquisition or transmission among drug users; and (4) substance misuse and chronic pain management. Stage II and Stage III efficacy research is especially encouraged. The opportunity supports diverse methods for improving treatment effectiveness, implementation, and long-term sustainability.
Eligible applicants include state, local, and tribal governments, public and private institutions of higher education, small and for-profit businesses, nonprofits with and without 501(c)(3) status, and other organizations such as faith-based and community organizations, Historically Black Colleges and Universities (HBCUs), and Native American-serving institutions. Non-U.S. entities and foreign organizations are also eligible.
The closing date for applications is March 21, 2025, with a posting date of May 9, 2022, and the most recent update on November 20, 2024. There is no cost-sharing or matching requirement. Applicants must follow NIH guidelines for submitting grant applications and are encouraged to review the full announcement for detailed instructions and evaluation criteria.
